Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yogesh Rathore

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Nuclear Medicine Communications|August 8, 2018
Concentration protocol of rhenium-188 perrhenate eluted from tungsten-188/rhenium-188 generator for the preparation of high-yield rhenium-188-labelled radiopharmaceuticalsAnupriya Chhabra, Yogesh Rathore, Priya Bhusari, et al.
Asia Oceania Journal of Nuclear Medicine & Biology|February 2, 2026
Potential role of <sup>68</sup>Ga- and <sup>177</sup>Lu-cyclic pentapeptides for in-vivo targeting CXCR4 receptor expression in chemotherapy relapse MCL patientTamanna Lakhanpal, Bhagwant Rai Mittal, Jaya Shukla, et al.
Clinical Nuclear Medicine|January 8, 2025
Re-Rechallenge 177 Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer : A Step FurtherPiyush Aggarwal, Vinisha Gunasekaran, Ashwani Sood, et al.
Nuclear Medicine Communications|June 17, 2025
Bifunctional chelator-plerixafor complex for targeting CXCR4 receptors: radiolabeling, in-vitro, and preclinical studyTamanna Lakhanpal, Jaya Shukla, Rajender Kumar, et al.
Nuclear Medicine Communications|April 1, 2022
Nuclear medicine in the management of superficial skin abnormalities and institutional experienceAnupriya Chhabra, Somit Pandey, Yogesh Rathore, et al.
Clinical Nuclear Medicine|April 5, 2024
Targeting Breast Cancer Using 177 Lu-Labeled Trastuzumab and Trastuzumab Fragment : First-in-Human Clinical ExperienceYogesh Rathore, Tamanna Lakhanpal, Sudipta Chakraborty, et al.
Dermatologic Therapy|June 17, 2017
Noninvasive treatment of keloid using customized Re-188 skin patchPriya Bhusari, Jaya Shukla, Munish Kumar, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|October 2, 2022
Cold kit for Rhenium-188 microspheres based selective intra-arterial therapy (SIRT): Preparation, characterization and feasibility studyJaya Shukla, Ankita Goyal, Anupriya Chhabra, et al.
Nuclear Medicine Communications|February 8, 2022
Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patientsYogesh Rathore, Jaya Shukla, Ishita Laroiya, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 22, 2025
Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathwaysSejal Chopra, Jaya Shukla, Priyavrat Purohit, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nuclear Medicine Communications|August 8, 2018
Concentration protocol of rhenium-188 perrhenate eluted from tungsten-188/rhenium-188 generator for the preparation of high-yield rhenium-188-labelled radiopharmaceuticalsAnupriya Chhabra, Yogesh Rathore, Priya Bhusari, et al.
Asia Oceania Journal of Nuclear Medicine & Biology|February 2, 2026
Potential role of <sup>68</sup>Ga- and <sup>177</sup>Lu-cyclic pentapeptides for in-vivo targeting CXCR4 receptor expression in chemotherapy relapse MCL patientTamanna Lakhanpal, Bhagwant Rai Mittal, Jaya Shukla, et al.
Clinical Nuclear Medicine|January 8, 2025
Re-Rechallenge 177 Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer : A Step FurtherPiyush Aggarwal, Vinisha Gunasekaran, Ashwani Sood, et al.
Nuclear Medicine Communications|June 17, 2025
Bifunctional chelator-plerixafor complex for targeting CXCR4 receptors: radiolabeling, in-vitro, and preclinical studyTamanna Lakhanpal, Jaya Shukla, Rajender Kumar, et al.
Nuclear Medicine Communications|April 1, 2022
Nuclear medicine in the management of superficial skin abnormalities and institutional experienceAnupriya Chhabra, Somit Pandey, Yogesh Rathore, et al.
Clinical Nuclear Medicine|April 5, 2024
Targeting Breast Cancer Using 177 Lu-Labeled Trastuzumab and Trastuzumab Fragment : First-in-Human Clinical ExperienceYogesh Rathore, Tamanna Lakhanpal, Sudipta Chakraborty, et al.
Dermatologic Therapy|June 17, 2017
Noninvasive treatment of keloid using customized Re-188 skin patchPriya Bhusari, Jaya Shukla, Munish Kumar, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|October 2, 2022
Cold kit for Rhenium-188 microspheres based selective intra-arterial therapy (SIRT): Preparation, characterization and feasibility studyJaya Shukla, Ankita Goyal, Anupriya Chhabra, et al.
Nuclear Medicine Communications|February 8, 2022
Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patientsYogesh Rathore, Jaya Shukla, Ishita Laroiya, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 22, 2025
Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathwaysSejal Chopra, Jaya Shukla, Priyavrat Purohit, et al.
Pageof 2